Granted Patent B1

US 12,234,236 · App. 18/884,965 · Granted Feb 25, 2025

Inventors: Bin Liang (Hong Kong, CN); Jinzi Jason Wu (Hong Kong, CN); Bailing Yang (Hong Kong, CN)

Assignee: Ascletis Pharma (China) Co., Limited

C07D471/04A61K31/437C07D519/00

Abstract

Claims (25)

1. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

2. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of a sodium salt, a calcium salt, a potassium salt, a magnesium salt and a lithium salt.

3. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of:

4. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of:

5. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is selected from the group consisting of:

6. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is selected from the group consisting of:

7. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is

8. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the pharmaceutically acceptable salt is

9. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the pharmaceutically acceptable salt is

10. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is

11. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is

12. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is

13. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the pharmaceutically acceptable salt is

14. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the pharmaceutically acceptable salt is

15. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is

16. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the pharmaceutically acceptable salt is

17. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the pharmaceutically acceptable salt is

18. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is

19. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the pharmaceutically acceptable salt is

20. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the pharmaceutically acceptable salt is

21. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the compound is

22. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the pharmaceutically acceptable salt is

23. The compound or the pharmaceutically acceptable salt thereof of claim 1 , wherein the pharmaceutically acceptable salt is

24. A compound, selected from the group consisting of:

25. A pharmaceutical composition, comprising the compound or the pharmaceutically acceptable salt thereof of claim 1 , and a pharmaceutically acceptable excipient.

Assignments (1)

Priority Claims (10)

Continuity (4)

References Cited (262)

Cited By (5)

US 12,419,874 US 12,617,783 US 12,703,700 US 12,709,614 US 12,729,200